anti-CD19 CAR T-cell therapy (Allogenica)

N/A

Report date: 2025/06/11 10:49:33

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (Allogenica)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocytes stimulantsB-lymphocyte antigen CD19 modulatorsImmunostimulants

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAllogenica Sas

China Registration ClassN/A

Develop Information

Active CompaniesAllogenica Sas

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A